Co-Diagnostics shares surge as company touts Bundibugyo Ebola assay strategy amid outbreak

By: Quiver PriceTracker

Posted: 2 days, 1 hour ago / May 19, 2026 2:51 p.m. UTC

CODX

Co-Diagnostics (CODX) is up 55.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The rally appears tied to a company announcement that it has completed an assay development strategy for the Bundibugyo virus (a strain of Ebola) during a newly escalated outbreak in Central Africa. Investors likely reacted to the potential for incremental demand and renewed attention on the company’s PCR platform if health agencies and partners move quickly to expand diagnostic testing capacity.

Details:

Co-Diagnostics said it completed an assay development strategy for Bundibugyo virus (BDBV), the strain implicated in the current Ebola outbreak in the Democratic Republic of the Congo and Uganda.

The company indicated it expects to be positioned to execute the strategy and rapidly make a test available if circumstances require it, while noting collaboration with public health organizations could be part of the pathway.

WHO described the event as Ebola disease caused by Bundibugyo virus and noted the outbreak was confirmed in mid-May, with cases in both DRC and Uganda.

WHO also stated the Director-General determined the event constitutes a Public Health Emergency of International Concern (PHEIC), underscoring the urgency for surveillance and laboratory diagnostic testing.

Sources:

Co-Diagnostics (press release), World Health Organization, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CODX Hedge Fund Activity

We have seen 6 institutional investors add shares of $CODX stock to their portfolio, and 28 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

RENAISSANCE TECHNOLOGIES LLC removed 24,344 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $45,279
GEODE CAPITAL MANAGEMENT, LLC removed 14,971 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $27,846
BLACKROCK, INC. removed 14,248 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $26,501
JANE STREET GROUP, LLC removed 8,031 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $14,937
VANGUARD GROUP INC added 6,772 shares (+11.9%) to their portfolio in Q4 2025, for an estimated $34,252
UBS GROUP AG added 6,320 shares (+603.1%) to their portfolio in Q1 2026, for an estimated $11,755
HRT FINANCIAL LP removed 4,976 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $25,168

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.